Overall survival (OS) · women with breast cancer and one to three positive lymph nodes
Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) probably leads to lower overall survival (OS) compared with no PMRT (moderate certainty).
1 finding from 1 review
Overall survival · health problem or population
Summary of Findings Table ‐ PBI?APBI showed no clear difference in overall survival compared with WBRT (high certainty).
1 finding from 1 review
Overall Survival** · locally advanced or metastatic breast cancer
PARPi‐containing regimen showed no clear difference in overall Survival** compared with non‐PARPi regimen (high certainty).
1 finding from 1 review
Intervention not reported
Overall survival · overweight and obese breast cancer survivors
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival · overweight and obese breast cancer survivors
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (OS) · women with metastatic triple‐negative breast cancer (mTNBC)
Platinum showed no clear difference in overall survival (OS) compared with non‐platinum regimens (moderate certainty).
1 finding from 1 review
Overall survival · women with early breast cancer
Taxane‐containing chemotherapy leads to lower overall survival compared with any chemotherapy without taxane (high certainty).
1 finding from 1 review
Overall survival · women with diagnosed breast cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival ( · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in overall survival ( compared with anthracyclines followed by taxane (moderate certainty).
1 finding from 1 review
Overall survival · adjuvant therapy for early breast cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · women with advanced breast cancer without bone metastases
Bisphosphonates showed no clear difference in overall survival compared with placebo/observation (high certainty).
1 finding from 1 review
Overall survival · women with metastatic breast cancer with bone metastases
Bisphosphonates showed no clear difference in overall survival compared with placebo/observation (moderate certainty).
1 finding from 1 review
Overall survival · women with early breast cancer
Bisphosphonates leads to lower overall survival compared with placebo/observation (high certainty).
1 finding from 1 review
Overall survival · women treated for early breast cancer
Summary of findings: Non‐intensive showed no clear difference in overall survival compared with intensive follow‐up (high certainty).
1 finding from 1 review
Overall survival · women treated for early breast cancer
Summary of findings: Decentralised showed no clear difference in overall survival compared with centralised follow‐up (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall survival · women with breast cancer
It is very uncertain whether the intervention changes overall survival (very low certainty).
1 finding from 1 review
Intervention not reported
Overall survival · women with breast cancer
It is very uncertain whether the intervention changes overall survival (very low certainty).
1 finding from 1 review
Survival ‐ overall · Women (70 years plus) with operable primary breast cancer
Surgery showed no clear difference in survival ‐ overall compared with primary endocrine therapy (low certainty).
1 finding from 1 review
Survival ‐ overall · Women (70 years plus) with operable primary breast cancer
Surgery plus endocrine therapy showed no clear difference in survival ‐ overall compared with primary endocrine therapy (low certainty).
1 finding from 1 review
Intervention not reported
Overall survival · patients with HER2‐positive metastatic breast cancer
The intervention probably leads to lower overall survival (moderate certainty).
1 finding from 1 review